Shares in commercial biotech company Allergy Therapeutics climbed 7.76% to 26.40p (13:20 BST) after the company announced positive top line results from phase II trials for a treatment for glass allergies.
AstraZeneca shares rose by 2.52% to 5,373p at 1100 BST after the US Food and Drug Administration approved Lokelma, which is designed to treat high blood potassium levels.
by James Faulkner | Equities |3 mins. to read Titon Holdings appears to be the closest thing to a UK-listed play on the opening-up of the North Korean economy.
by Victor Hill | Equities |14 mins. to read In a few short months Facebook has gone from being the tech giant everybody likes to global bogeyman. Are all the little angry faces really justified? Victor Hill investigates.
Material contained within Master Investor Magazine and its website is for general information purposes only and is not intended to be relied upon by individual readers in making (or refraining from making) any specific investment decisions. Master Investor Ltd. does not accept any liability for any losses suffered by any user as a result or any such decision.
Ingen kommentarer:
Send en kommentar